AlphAIAlphAI — Financial news for AI agents
investing.comOCT 72 min read$MDT

Medtronic sets final exchange ratio for MiniMed split-off

Medtronic (NYSE:MDT) set the final exchange ratio for its offer to swap shares for MiniMed (NASDAQ:MMED) stock at 4.5939. The company will exchange up to 225,361,295 MiniMed shares. If oversubscribed, Medtronic may exchange additional shares without extending the offer. The exchange offer expires at midnight on Friday.

Original reporting
investing.com
Published Oct 7, 2026, 9:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 9:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
$MDT
Neutral
high confidence
Mentioned
$MDT · $MMED
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MDTNeutralHigh
01

Why it matters

The final ratio sets the conversion mechanics, influencing valuation and liquidity for both companies and may trigger trading activity around the deadline.

02

Market read

Newly disclosed exchange terms provide actionable insight for traders in Medtronic and MiniMed stocks.

03

What to watch

Potential regulatory approvals and integration costs could affect the ultimate value of the split‑off.

Relevance 8/10Novelty 8/10Timing: immediate

Background

Medtronic is executing a spin‑off of its MiniMed diabetes business, offering Medtronic shareholders a share‑exchange at a fixed ratio.

Company-level read

Ticker impact

$MDTNeutralHigh confidence
Context

Medtronic announced the final exchange ratio for its split‑off of MiniMed, setting the terms of the share‑exchange offer.

Expected impact

potential modest downside for MDT as the market prices the dilution; possible upside for MMED if the exchange is viewed as value‑creating.

Evidence & confidence

Deal terms are newly disclosed, affecting valuation expectations for both entities.

$MMEDNeutralHigh confidence
Context

MiniMed is the target of Medtronic's split‑off, with a defined exchange ratio of 4.5939 shares per Medtronic share.

Expected impact

potential modest upside for MMED as the conversion may be seen as a catalyst.

Evidence & confidence

Newly disclosed terms directly affect MiniMed's share supply and investor perception.

Market effects

Sector

The healthcare device sector may see increased M&A activity as the split‑off clarifies Medtronic's focus.

Regional

U.S. markets could react to the deal, especially the med‑tech segment.

Global

Limited to investors tracking Medtronic and MiniMed; no broader global effect.

Counterpoint

What could challenge this read

Some investors may view the capped ratio as a sign of Medtronic's limited confidence in MiniMed, suggesting a sell on MDT.

Key entities

  • Company
    Medtronic plc

    Medical device manufacturer executing the split‑off.

  • Company
    MiniMed Group, Inc.

    Diabetes technology business being spun off.

Read at source← All news

StoryMedtronic Reports Oversubscribed MiniMed Split-Off and Preliminary Proration

Also covered by

6 outlets

Related articles

OCT 23
$MDTMed

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

Medtronic's MiniMed Vivera algorithm showed promise in managing type 1 diabetes without meal announcements, with participants maintaining glycemic targets. The twiist AID system from Sequel Med Tech received FDA clearance for type 2 diabetes, showing improved HbA1c and time-in-range in trials. Both systems aim to reduce user input in automated insulin delivery.

hcplive.com2 min
OCT 23
$MDTMed

Medtronic reports real-world findings for cardiac ablation systems

Medtronic reported positive real-world registry findings for its cardiac ablation technologies, presented at the APHRS 2026 meeting. The PulseSelect PFA system showed a 100% success rate in AFib patients with a 0.09% complication rate. The Affera system with Sphere-9 catheter had a 1.1% major complication rate in AFib patients and an 87% success rate in VT patients. Medtronic's vice-president expressed confidence in the safety and performance of these technologies.

finance.yahoo.com2 min
OCT 22
$JNJMedAI 9/10

J&J, Medtronic present pulsed field ablation data from global real-world use

J&J and Medtronic presented data on their pulsed field ablation platforms at the Asia Pacific Heart Rhythm Society meeting. J&J's Varipulse Pro showed 100% procedural success in 225 European patients with no major complications. Medtronic's PulseSelect had a 100% success rate and 0.09% major complication rate in 1,160 global patients. Both companies also shared data on upcoming systems and catheters.

massdevice.com2 min
OCT 20
MedAI 8/10

Medtronic’s next-gen pacemaker portfolio secures CE mark

Medtronic's Vitalis portfolio of next-gen pacemakers, designed for conduction system pacing (CSP) therapy, received a CE mark. The five pacemakers include advanced features like AdaptivCSP for heart synchrony. Medtronic claims this offers a more physiologic pacing option. GlobalData reports Medtronic leads the US pacemaker market with 58.7% share in 2025, with the global market growing at a 4.9% CAGR.

medicaldevice-network.com2 min
OCT 19
$MDTHigh

Medtronic nets CE Mark for Vitalis family of conduction system pacemakers

Medtronic (MDT) received CE Mark approval for its Vitalis family of pacemakers, designed for conduction system pacing. The portfolio includes five devices targeting various patient needs, such as the ReSyncra CSP for cardiac resynchronization therapy. The devices aim to improve heart synchronization by targeting conductive tissues, offering personalized therapy and remote monitoring. According to Medtronic, the portfolio builds on its history in cardiac electrophysiology therapies.

massdevice.com2 min